Evidence map›Paper›PMID 29315663›Full record

ArticleAllergy2018

Circulating 25-hydroxyvitamin D, nasopharyngeal airway metabolome, and bronchiolitis severity.

K Hasegawa, C J Stewart, J C Celedón, J M Mansbach, C Tierney, C A Camargo

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Metabolomics in the prevention and management of asthma.Expert review of respiratory medicine · 2019
    Article
  9. Article
  10. Article
  11. Circulating 25-hydroxyvitamin D, nasopharyngeal microbiota, and bronchiolitis severity.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

K HasegawaDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5739-7999
C J StewartAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
J C CeledónDivision of Pulmonary Medicine, Allergy, and Immunology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-6139-5320
J M MansbachDepartment of Medicine, Boston Children's Hospital, Boston, MA, USA.
C TierneyDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
C A CamargoDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USBaylor College of Medicine · USBoston Children's Hospital · USUniversity of Pittsburgh · US

Funding

Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUH3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARLOS ARTURO CAMARGO · 2018 to 2026
$12.1M
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohortR01AI127507 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO, FREISHTAT, ROBERT J · 2017 to 2021
$8.0M
Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUG3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2016 to 2024
$6.8M
Prospective Cohort Study of Severe Bronchiolitis and Risk of Recurrent WheezingU01AI087881 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2011 to 2016
$6.2M
Airway metagenome & metabolome in bronchiolitis and risk of asthma: MARC-35 cohortR01AI134940 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.0M
Cytokines & transcriptomes in rhinovirus bronchiolitis and risk of incident asthmaR21HL129909 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2015 to 2016
$506k
NHLBI NIH HHS R21 HL129909NIAID NIH HHS R01 AI127507NIAID NIH HHS R01 AI134940NIAID NIH HHS U01 AI087881NIH HHS UG3 OD023253NIH HHS UH3 OD023253
6 · The paper itself

Abstract

Low circulating 25-hydroxyvitamin D (25OHD) levels are a risk factor for acute respiratory infection (eg, bronchiolitis) in children. However, little is known about the relation of circulating 25OHD with the many downstream functional molecules in target organs-such as the airway-and with clinical outcomes. In this prospective multicenter study of infants (age <1 year) hospitalized with bronchiolitis, we measured serum 25OHD levels and profiled the metabolome of 144 nasopharyngeal airway samples. Among 254 metabolites identified, we defined a set of 20 metabolites that are related to lower serum 25OHD and higher vitamin D-binding protein levels. Of these metabolites, 9 metabolites were associated with a significantly higher risk of positive pressure ventilation use. These metabolites were glycerophosphocholines esterified with proinflammatory fatty acids (palmitate, arachidonate, linoleate, and stearate), sphingomyelins, alpha-hydroxyisovalerate, 2-hydroxybutyrate, and 3-(4-hydroxyphenyl)lactate (all FDR<0.05). Based on the multicenter data, vitamin D-related airway metabolites were associated with risks of bronchiolitis severity.

Indexed as

BronchiolitisFemaleHumansInfantInfant, NewbornMaleMetabolomeNasal MucosaProspective StudiesVitamin D25-hydroxyvitamin DVitamin Dairwaybronchiolitismetabolomeseverityvitamin D

Identifiers

PMID29315663
PMCPMC6167253
OpenAlexW2784299443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.